PJP is trading at $126.44, up 4.50% in pre-market from its October 8 close of $120.99, based on the supplied price context.

  • PJP is the Invesco Pharmaceuticals ETF; available coverage did not identify a direct catalyst for its pre-market jump.
  • Pfizer’s FDA approval of a TUKYSA regimen is relevant pharmaceutical-sector news, but no source links it to PJP’s move.